Literature DB >> 30472180

Ischemic-type biliary lesions: A leading indication of liver retransplantation with excellent results.

Astrid Schielke1, Olivier Scatton2, Pierre-Yves Boelle3, Fabiano Perdigao1, Denis Bernard4, Olivier Soubrane5, Filomena Conti6.   

Abstract

BACKGROUND: Liver retransplantation (RLT) is the only life-saving treatment option for patients with a failing graft, but it remains a major challenge because of inferior outcomes and technical difficulties.
METHODS: This study aimed to evaluate the outcomes of and risk factors for adult RLT in a single center, focusing on the etiology of graft failure. Between 1987 and 2011, 1592 liver transplants (LTs) and 143 RLTs (9%) were performed at our institution.
RESULTS: The 1-, 5- and 10-year patient survival rates after RLT were 60%, 52% and 39%, and the graft survival rates were 55%, 46% and 32%. The 90-day mortality rate was 32%, mainly due to septic complications (45% of deaths). Ischemic-type biliary lesions (ITBL) were the leading indication for RLT (23%), and patient survival was significantly better in patients retransplanted for ITBL than for any other indication (P<0.02). Indications other than ITBL (P=0.015), the transfusion of more than 7 units (P=0.006) and preoperative dialysis (P=0.005) were the three parameters associated with poor survival after RLT.
CONCLUSION: Patients with ITBL benefit the most from elective RLT.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Ischemic-type biliary lesion; Liver retransplantation; Organ shortage; Performance status

Mesh:

Year:  2018        PMID: 30472180     DOI: 10.1016/j.clinre.2017.11.005

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  1 in total

1.  Artificial Intelligence Algorithm-Based CTA Imaging for Diagnosing Ischemic Type Biliary Lesions after Orthotopic Liver Transplantation.

Authors:  Zhenxing Yu; Guixue Ou; Ruihua Wang; Qinghua Zhang
Journal:  Comput Math Methods Med       Date:  2022-01-04       Impact factor: 2.238

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.